RxDoctor Payments Data

Mitzy Stewart, APRN

Psychiatric/Mental Health · Layton, UTNPI 1538147418

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 33.1% of the total. Reporting peaked in 2023 at $1,384 and has fallen 93.6% since, to $89 in 2024.

$2,718in general payments, 2019–2025

Across 105 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$901
  • Otsuka America Pharmaceutical, Inc.$504
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$364
  • Alkermes, Inc.$214
  • Sunovion Pharmaceuticals Inc.$152
  • Neurocrine Biosciences, Inc.$126
  • plus $458 from 6 others

What the payments were for

  • Food & beverage$2,718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,718 in reported general payments places this provider in the 85th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$7,141
Medicare patients
14
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide11$5,063
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine44$1,548
Atomoxetine Hcl17$1,503
Quetiapine Fumarate25$399
Lamotrigine29$364
Divalproex Sodium ErDivalproex Sodium11$354
Prazosin Hcl12$347
Escitalopram Oxalate30$339
Ziprasidone Hcl13$275
Buspirone Hcl17$210
Citalopram HbrCitalopram Hydrobromide12$205
Lorazepam43$130
Trazodone Hcl27$119
Clonazepam16$39

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →